Company Filing History:
Years Active: 2020-2025
Title: Innovations by Thomas Seidl in Diabetes Management
Introduction
Thomas Seidl is an accomplished inventor based in Tigard, Oregon, known for his significant contributions to diabetes management technologies. With a total of four patents to his name, Seidl has focused on developing methods and systems that enhance insulin delivery and glucose measurement for individuals with diabetes.
Latest Patents
One of Seidl's latest patents is titled "Methods and systems for insulin delivery and glucose measurement." This innovative method involves positioning an insulin delivery device on a subject's body through a single puncture site. The device not only delivers insulin or insulin analog formulations but also measures glucose concentration simultaneously, ensuring a sensitivity of at least 50% of the sensor's initial sensitivity. Another notable patent is "Biosensors and methods for determining analyte concentration in the kinetic potential region of redox mediators." This patent describes methods and devices that determine analyte concentration using output currents from an input potential in the kinetic potential region of a redox mediator, enhancing the accuracy of glucose monitoring.
Career Highlights
Seidl's career is marked by his dedication to improving diabetes care through innovative technology. His work at Pacific Diabetes Technologies Inc. has positioned him as a key player in the field of medical devices aimed at diabetes management. His inventions have the potential to significantly improve the quality of life for individuals living with diabetes.
Collaborations
Seidl has collaborated with notable professionals in the field, including William Kenneth Ward and Robert S. Cargill. These partnerships have contributed to the development and refinement of his innovative technologies.
Conclusion
Thomas Seidl's work exemplifies the intersection of innovation and healthcare, particularly in diabetes management. His patents reflect a commitment to enhancing the lives of those affected by diabetes through advanced technology.